The FDA declined to approve one of biotech's most closely watched cancer drugs

The FDA declined to approve Summit Therapeutics' lung-cancer drug, ivonescimab, citing insufficient evidence of improved overall survival. The drug is licensed from Akeso. Summit's stock (SMMT) fell 10%, and Akeso's (9926) shares dropped 22.1%. Ivonescimab is already approved in China and is being tested for other cancers. Summit's stock is down 19.2% this year, while the biotech ETF XBI is up 23.9%.

Original reporting
Published Nov 16, 2026, 3:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SMMT
Bearish
high confidence
Mentioned
$SMMT
Relevance
9/10
AlphAI data visualization · based on morningstar.com
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The FDA denial centers on the absence of statistically significant overall survival benefit, not just a lack of efficacy signal, which can materially change the regulatory and trial strategy for the program.

02

Market read

A direct FDA regulatory decision for a closely watched oncology asset drives immediate repricing of approval odds and timelines.

03

What to watch

The article notes ivonescimab is already approved in China and is being tested in multiple cancers, which could partially offset US approval delays.

Relevance 9/10Novelty 9/10Timing: Monday morning trading reaction after the FDA declined approval on Sunday.

Background

Summit licensed ivonescimab from Akeso in 2022 and is pursuing FDA approval for metastatic non-small-cell lung cancer based on the Phase 3 HARMONi trial.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA declined to approve Summit Therapeutics' lung-cancer drug, saying it must prove statistically significant overall survival benefit.

Expected impact

Likely further pressure as investors reprice the probability and timing of U.S. approval for ivonescimab.

Evidence & confidence

The FDA explicitly required overall survival statistical significance, rejecting the current Phase 3 evidence basis.

Market effects

Raises scrutiny for PD-1/VEGF combination oncology programs where progression-free survival improves but overall survival is not statistically significant.

US biotech sentiment likely negative; foreign-listed Akeso also fell sharply, suggesting read-across risk for partnered assets.

Highlights FDA’s strict overall-survival bar, which can affect global development strategies and investor expectations for similar trials.

Counterpoint

The FDA’s feedback may still allow a path to approval via additional analyses or new trials, limiting long-term impairment if the company can generate overall-survival evidence.

Key entities

  • Summit Therapeutics

    US biotech developing ivonescimab for metastatic non-small-cell lung cancer; FDA declined approval.

  • ivonescimab

    PD-1 and VEGF-targeting lung-cancer therapy licensed by Summit from Akeso.

  • Akeso

    Chinese biotech that developed ivonescimab and saw its Hong Kong shares fall.

  • FDA

    Required statistically significant overall survival improvement for approval.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.